BackIterum Therapeutics Plc Overview

Iterum Therapeutics Plc Profit Margin

Latest profit margin for Iterum Therapeutics Plc: -69.13% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-2302.31%

As of Sep 2025

Annual Profit Margin (TTM)

-6913.08%
492.80% YoY

Trailing 12 months ending Sep 2025

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Iterum Therapeutics Plc (ITRM) FAQ

Iterum Therapeutics Plc posts a profit margin of -69.13% as of September 2025. That compares with -11.66% in the prior-year period — down 492.8% year over year. That is below the Healthcare sector average of 15.52%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Iterum Therapeutics Plc's profit margin was -11.66%. The latest reading is -69.13% — a 492.8% year-over-year decrease (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.52% is typical. Iterum Therapeutics Plc's -69.13% is lower that level. That is roughly 44642.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Iterum Therapeutics Plc's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -69.13% as of September 2025; use YoY and peer views to separate noise from signal.

Context for ITRM's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.52%), and (3) consistency with growth and profitability. This page covers the first two; Iterum Therapeutics Plc's other metric pages and overview cover the third.